Table 1 Baseline data of all HCC patients
From: Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma
Characteristic | Type | n | Proportion (%) |
|---|---|---|---|
Age |  <  = 65 | 235 | 62.33 |
 > 65 | 141 | 37.40 | |
unknow | 1 | 0.27 | |
Gender | FEMALE | 122 | 32.36 |
MALE | 255 | 67.64 | |
Grade | G1–2 | 235 | 62.33 |
G3–4 | 137 | 36.34 | |
unknow | 5 | 1.33 | |
Stage | Stage I–II | 262 | 69.50 |
Stage III–IV | 91 | 24.14 | |
unknow | 24 | 6.37 | |
T stage | T1–2 | 280 | 74.27 |
T3–4 | 94 | 24.93 | |
unknow | 3 | 0.80 | |
M stage | M0 | 272 | 72.15 |
M1 | 4 | 1.06 | |
unknow | 101 | 26.79 | |
N stage | N0 | 257 | 68.17 |
N1 | 4 | 1.06 | |
unknow | 116 | 30.77 |